KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Amgen (AMGN) over the last 13 years, with Q4 2025 value amounting to $125.0 million.

  • Amgen's Share-based Compensation fell 671.64% to $125.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $494.0 million, marking a year-over-year decrease of 679.25%. This contributed to the annual value of $494.0 million for FY2025, which is 679.25% down from last year.
  • According to the latest figures from Q4 2025, Amgen's Share-based Compensation is $125.0 million, which was down 671.64% from $127.0 million recorded in Q3 2025.
  • Over the past 5 years, Amgen's Share-based Compensation peaked at $161.0 million during Q4 2023, and registered a low of $47.0 million during Q1 2023.
  • In the last 3 years, Amgen's Share-based Compensation had a median value of $126.0 million in 2025 and averaged $121.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 11914.89% in 2024, then tumbled by 1747.57% in 2025.
  • Over the past 3 years, Amgen's Share-based Compensation (Quarter) stood at $161.0 million in 2023, then dropped by 16.77% to $134.0 million in 2024, then decreased by 6.72% to $125.0 million in 2025.
  • Its Share-based Compensation was $125.0 million in Q4 2025, compared to $127.0 million in Q3 2025 and $157.0 million in Q2 2025.